ASH 2025 | A Phase II trial of asciminib for newly diagnosed chronic myeloid leukemia
Fadi Haddad
• 7 Dec 2025
Fadi Haddad, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from a Phase II trial (NCT06236724) evaluating asciminib in patients with newly diagnosed chronic myeloid leukemia (CML). Dr Haddad reports high rates of early molecular and cytogenetic responses with a generally favorable safety profile, supporting asciminib as a promising frontline option. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
